Urologic cancer drugs
Companies developing drugs to treat bladder, kidney and prostate cancer.
+56.3%
over 1 year · S&P 500 +11.6%
Key indicators
Health
51 / 100
Fragile
Solid
Up over 1 year
8 of 12
Volatility
65%
Calm
Choppy
Profitability
−244%
Low
High
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 12 companies
EXEL
+58.3%
IBRX
+192.2%
CGON
+88.8%
RCUS
VIR
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
E
Exelixis
EXEL
40.9%
+58.3%
I
ImmunityBio
IBRX
17.3%
+192.2%
C
CG Oncology
CGON
15.8%
+88.8%
X
Xencor
XNCR
6.8%
+157.7%
R
Arcus Biosciences
RCUS
6.1%
−12.9%
V
Vir Biotechnology
VIR
4.5%
+74.4%
T
Tyra Biosciences
TYRA
3.6%
+29.4%
O
Oric Pharmaceuticals
ORIC
2.3%
−37.0%
J
Janux Therapeutics
JANX
1.7%
−60.1%
R
Relmada Therapeutics
RLMD
1.1%
+7.7%
T
Telix Pharmaceuticals
TLX
−5.9%
U
UroGen Pharma
URGN
+4.1%